Yantai Zhenghai Bio-Tech Co Ltd Market Cap ($364.54 Million)
Market Cap & Net Worth: Yantai Zhenghai Bio-Tech Co Ltd (300653)
Yantai Zhenghai Bio-Tech Co Ltd market cap. Yantai Zhenghai Bio-Tech Co Ltd (SHE:300653) has a market capitalization of $364.54 Million (CN¥2.49 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #13555 globally and #3980 in its home market, demonstrating a -7.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yantai Zhenghai Bio-Tech Co Ltd's stock price CN¥13.84 by its total outstanding shares 180000000 (180.00 Million). Also see Yantai Zhenghai Bio-Tech Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Yantai Zhenghai Bio-Tech Co Ltd Market Cap History (2017–2026)
Yantai Zhenghai Bio-Tech Co Ltd market cap history from 2017 to 2026. Data shows growth from $366.95 Million to $364.54 Million (7.89% CAGR). Check today's stock price for Yantai Zhenghai Bio-Tech Co Ltd for real-time trading data and today's change.
Yantai Zhenghai Bio-Tech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yantai Zhenghai Bio-Tech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300653 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.44x
Yantai Zhenghai Bio-Tech Co Ltd's market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.38x
Yantai Zhenghai Bio-Tech Co Ltd's market cap is 6.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $366.95 Million | $182.78 Million | $61.67 Million | 2.01x | 5.95x |
| 2018 | $491.64 Million | $215.54 Million | $85.82 Million | 2.28x | 5.73x |
| 2019 | $757.37 Million | $279.81 Million | $107.39 Million | 2.71x | 7.05x |
| 2020 | $920.05 Million | $293.28 Million | $118.33 Million | 3.14x | 7.78x |
| 2021 | $1.09 Billion | $400.18 Million | $168.55 Million | 2.72x | 6.46x |
| 2022 | $1.08 Billion | $433.22 Million | $185.44 Million | 2.48x | 5.80x |
| 2023 | $737.53 Million | $413.65 Million | $190.96 Million | 1.78x | 3.86x |
| 2024 | $561.03 Million | $363.23 Million | $134.64 Million | 1.54x | 4.17x |
| 2025 | $526.00 Million | $364.14 Million | $82.41 Million | 1.44x | 6.38x |
Competitor Companies of 300653 by Market Capitalization
Companies near Yantai Zhenghai Bio-Tech Co Ltd in the global market cap rankings as of November 5, 2026. Also see Yantai Zhenghai Bio-Tech Co Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Yantai Zhenghai Bio-Tech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Yantai Zhenghai Bio-Tech Co Ltd (2017–2026)
Market capitalization of Yantai Zhenghai Bio-Tech Co Ltd from 2017 to today. Between 2017 and today, Yantai Zhenghai Bio-Tech Co Ltd's market cap moved from $366.95 Million to $ 364.54 Million, with a yearly change of 7.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥364.54 Million | -30.70% |
| 2025 | CN¥526.00 Million | -6.24% |
| 2024 | CN¥561.03 Million | -23.93% |
| 2023 | CN¥737.53 Million | -31.41% |
| 2022 | CN¥1.08 Billion | -1.23% |
| 2021 | CN¥1.09 Billion | +18.33% |
| 2020 | CN¥920.05 Million | +21.48% |
| 2019 | CN¥757.37 Million | +54.05% |
| 2018 | CN¥491.64 Million | +33.98% |
| 2017 | CN¥366.95 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Yantai Zhenghai Bio-Tech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $364.54 Million USD |
| MoneyControl | $364.54 Million USD |
| MarketWatch | $364.54 Million USD |
| marketcap.company | $364.54 Million USD |
| Reuters | $364.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral restoration membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etching agent, dental pit and fissure sealant, active biol… Read more